{"disease":{"id":"tuberculosis","name":"Tuberculosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":1,"trial_count":19},"drugs":{"marketed":[{"drug_id":"bedaquiline","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sirturo","generic_name":"bedaquiline","company_name":"Janssen Therap","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Diarylquinoline Antimycobacterial","quality_score":75,"revenue":"400","mechanism":"Sirturo works by blocking the potassium voltage-gated channel subfamily H member 2, which is essential for the survival of Mycobacterium tuberculosis bacteria."},{"drug_id":"bedaquiline","indication_name":"Drug resistant tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sirturo","generic_name":"bedaquiline","company_name":"Janssen Therap","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Diarylquinoline Antimycobacterial","quality_score":75,"revenue":"400","mechanism":"Sirturo works by blocking the potassium voltage-gated channel subfamily H member 2, which is essential for the survival of Mycobacterium tuberculosis bacteria."},{"drug_id":"cycloserine","indication_name":"Active Extrapulmonary Tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pyrazinamide","indication_name":"Initial treatment of active tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrazinamide","generic_name":"PYRAZINAMIDE","company_name":"Dava Pharms Inc","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"pyrazinamide","indication_name":"Treatment of drug-resistant tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrazinamide","generic_name":"PYRAZINAMIDE","company_name":"Dava Pharms Inc","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Fulminating or disseminated pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tuberculin-purified-protein-derivative","indication_name":"Detection of M. tuberculosis infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tuberculin purified protein derivative","company_name":"Assiut University","drug_phase":"marketed","molecular_target":"","drug_class":"Skin Test Antigen [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"enviomycin","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tuberactinomycin N","generic_name":"ENVIOMYCIN","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"enviomycin","quality_score":24,"revenue":null,"mechanism":"Enviomycin works by inhibiting bacterial growth and replication."},{"drug_id":"cycloserine","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cycloserine","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"aminosalicylate-sodium","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apacil","generic_name":"AMINOSALICYLATE SODIUM","company_name":"Consolidated Midland","drug_phase":"marketed","molecular_target":"Tyrosine-protein phosphatase non-receptor type 1","drug_class":"aminosalicylic acid","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"aminosalicylate-sodium","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apacil","generic_name":"AMINOSALICYLATE SODIUM","company_name":"Consolidated Midland","drug_phase":"marketed","molecular_target":"Tyrosine-protein phosphatase non-receptor type 1","drug_class":"aminosalicylic acid","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"tuberculin","indication_name":"infection with Mycobacterium tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aplisol","generic_name":"TUBERCULIN","company_name":"ENDO USA, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Skin Test Antigen [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tuberculin","indication_name":"M. tuberculosis infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aplisol","generic_name":"TUBERCULIN","company_name":"ENDO USA, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Skin Test Antigen [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pyrazinamide","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrazinamide","generic_name":"PYRAZINAMIDE","company_name":"Dava Pharms Inc","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"pyrazinamide","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrazinamide","generic_name":"PYRAZINAMIDE","company_name":"Dava Pharms Inc","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"pyrazinamide","indication_name":"Tuberculosis of meninges","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrazinamide","generic_name":"PYRAZINAMIDE","company_name":"Dava Pharms Inc","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"rifampicin","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rifadin","generic_name":"Rifampicin","company_name":"Sanofi Aventis Us","drug_phase":"marketed","molecular_target":"Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"rifampicin","indication_name":"Inactive tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rifadin","generic_name":"Rifampicin","company_name":"Sanofi Aventis Us","drug_phase":"marketed","molecular_target":"Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"rifampicin","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rifadin","generic_name":"Rifampicin","company_name":"Sanofi Aventis Us","drug_phase":"marketed","molecular_target":"Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"isoniazid","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoniazid","generic_name":"ISONIAZID","company_name":"Epic Pharma Llc","drug_phase":"marketed","molecular_target":"Myeloperoxidase","drug_class":"Antimycobacterial [EPC]","quality_score":69,"revenue":null,"mechanism":"Isoniazid works by inhibiting the enzyme myeloperoxidase, which is essential for the survival of Mycobacterium tuberculosis."},{"drug_id":"isoniazid","indication_name":"Inactive tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoniazid","generic_name":"ISONIAZID","company_name":"Epic Pharma Llc","drug_phase":"marketed","molecular_target":"Myeloperoxidase","drug_class":"Antimycobacterial [EPC]","quality_score":69,"revenue":null,"mechanism":"Isoniazid works by inhibiting the enzyme myeloperoxidase, which is essential for the survival of Mycobacterium tuberculosis."},{"drug_id":"isoniazid","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoniazid","generic_name":"ISONIAZID","company_name":"Epic Pharma Llc","drug_phase":"marketed","molecular_target":"Myeloperoxidase","drug_class":"Antimycobacterial [EPC]","quality_score":69,"revenue":null,"mechanism":"Isoniazid works by inhibiting the enzyme myeloperoxidase, which is essential for the survival of Mycobacterium tuberculosis."},{"drug_id":"cortisone-acetate","indication_name":"Miliary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"rifapentine","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Priftin","generic_name":"RIFAPENTINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Rifamycin Antimycobacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Priftin works by inhibiting the synthesis of mycolic acid, a key component of the Mycobacterium tuberculosis cell wall."},{"drug_id":"dexamethasone","indication_name":"Miliary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Tuberculosis Meningitis Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"isoniazide","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"isoniazide","company_name":"Bridge BioResearch Ltd.","drug_phase":"phase_2","molecular_target":"Myeloperoxidase, Cytochrome P450 3A4, Cytochrome P450 3A5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"isoniazide","indication_name":"Inactive tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"isoniazide","company_name":"Bridge BioResearch Ltd.","drug_phase":"phase_2","molecular_target":"Myeloperoxidase, Cytochrome P450 3A4, Cytochrome P450 3A5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"isoniazide","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"isoniazide","company_name":"Bridge BioResearch Ltd.","drug_phase":"phase_2","molecular_target":"Myeloperoxidase, Cytochrome P450 3A4, Cytochrome P450 3A5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"thioacetazone","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"thioacetazone","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminosalicylic-acid-resin-complex","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"REZIPAS","generic_name":"AMINOSALICYLIC ACID RESIN COMPLEX","company_name":"BRISTOL MYERS SQUIBB","drug_phase":"marketed","molecular_target":"Tyrosine-protein phosphatase non-receptor type 1, Cyclooxygenase, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"aminosalicylic-acid-resin-complex","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"REZIPAS","generic_name":"AMINOSALICYLIC ACID RESIN COMPLEX","company_name":"BRISTOL MYERS SQUIBB","drug_phase":"marketed","molecular_target":"Tyrosine-protein phosphatase non-receptor type 1, Cyclooxygenase, 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolone","indication_name":"Miliary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"ftivazide","indication_name":"Tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ftivazid","generic_name":"FTIVAZIDE","company_name":"","drug_phase":"phase_2","molecular_target":"Myeloperoxidase","drug_class":"ftivazide","quality_score":null,"revenue":null,"mechanism":"Ftivazid works by inhibiting the activity of myeloperoxidase, an enzyme that contributes to the development of tuberculosis."},{"drug_id":"ethambutol","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Myambutol","generic_name":"ETHAMBUTOL","company_name":"Kanchan Hlthcare","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"ethambutol","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Myambutol","generic_name":"ETHAMBUTOL","company_name":"Kanchan Hlthcare","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Antimycobacterial","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Miliary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"rifampin","indication_name":"Tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIFAMPIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA-dependent RNA polymerase","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms."},{"drug_id":"ethionamide","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trecator","generic_name":"ETHIONAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Antimycobacterial","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Fulminating or disseminated pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"delamanid","indication_name":"Drug resistant tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltyba","generic_name":"delamanid","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"delamanid","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aminosalicylic-acid","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apacil","generic_name":"AMINOSALICYLIC ACID","company_name":"Consolidated Midland","drug_phase":"marketed","molecular_target":"Tyrosine-protein phosphatase non-receptor type 1","drug_class":"aminosalicylic acid","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"aminosalicylic-acid","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Apacil","generic_name":"AMINOSALICYLIC ACID","company_name":"Consolidated Midland","drug_phase":"marketed","molecular_target":"Tyrosine-protein phosphatase non-receptor type 1","drug_class":"aminosalicylic acid","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Miliary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"capreomycin","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Capastat Sulfate","generic_name":"CAPREOMYCIN","company_name":"Epic Pharma Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Antimycobacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"capreomycin","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Capastat Sulfate","generic_name":"CAPREOMYCIN","company_name":"Epic Pharma Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Antimycobacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Miliary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Miliary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Miliary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"seromycin","indication_name":"Acute tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"seromycin","company_name":"Massachusetts General Hospital","drug_phase":"discontinued","molecular_target":"Cytochrome P450 3A4, Glutamate receptor ionotropic, NMDA 1, Glutamate receptor ionotropic, NMDA 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"seromycin","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"seromycin","company_name":"Massachusetts General Hospital","drug_phase":"discontinued","molecular_target":"Cytochrome P450 3A4, Glutamate receptor ionotropic, NMDA 1, Glutamate receptor ionotropic, NMDA 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ethionamide","indication_name":"Pulmonary tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trecator","generic_name":"ETHIONAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Antimycobacterial","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"cycloserine","indication_name":"Active Pulmonary Tuberculosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"rifampin","indication_name":"Pulmonary Tuberculosis","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIFAMPIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA-dependent RNA polymerase","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms."},{"drug_id":"rifampin","indication_name":"Rifampicin-resistant Tuberculosis","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RIFAMPIN","company_name":"","drug_phase":"marketed","molecular_target":"DNA-dependent RNA polymerase","drug_class":"Rifamycin Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms."},{"drug_id":"cephalexin","indication_name":"Tuberculosis","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."}],"offLabel":[],"totalMarketed":54,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT03948698","title":"TB Innovation Project: A Pre- and Post- Implementation Assessment (TIPPI)","phase":"","overall_status":"COMPLETED","enrollment_count":4159533,"lead_sponsor_name":"Elizabeth Glaser Pediatric AIDS Foundation","has_results":true},{"nct_id":"NCT07126041","title":"Scalable Public Health Empowerment, Research, and Education Sites (SPHERES)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1750000,"lead_sponsor_name":"Oxford University Clinical Research Unit Indonesia","has_results":false},{"nct_id":"NCT06017843","title":"Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding","phase":"NA","overall_status":"RECRUITING","enrollment_count":180000,"lead_sponsor_name":"Centre for Global Public Health Pakistan","has_results":false},{"nct_id":"NCT06719193","title":"DeMONSTRATE-TB Study in Ethiopia","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":131438,"lead_sponsor_name":"Management Sciences for Health","has_results":false},{"nct_id":"NCT03106727","title":"Evaluating the Impact of a Community Health Worker Program in Neno, Malawi","phase":"NA","overall_status":"COMPLETED","enrollment_count":122395,"lead_sponsor_name":"Partners in Health","has_results":false},{"nct_id":"NCT05406453","title":"Whole Genome Sequencing of Tuberculosis for Disease Control in Madagascar","phase":"NA","overall_status":"COMPLETED","enrollment_count":98362,"lead_sponsor_name":"Institut Pasteur de Madagascar","has_results":false},{"nct_id":"NCT06702774","title":"Research on Key Interventional Technologies for Controlling the Epidemic in High-prevalence Areas of Tuberculosis in Guangxi, China","phase":"NA","overall_status":"RECRUITING","enrollment_count":72000,"lead_sponsor_name":"University of Toronto","has_results":false},{"nct_id":"NCT07420881","title":"Start4All - Start Taking Action for TB Diagnosis (DARE-TB)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":60000,"lead_sponsor_name":"Liverpool School of Tropical Medicine","has_results":false},{"nct_id":"NCT04466488","title":"Prevent TB: Choice Architecture for TPT Delivery","phase":"NA","overall_status":"COMPLETED","enrollment_count":50798,"lead_sponsor_name":"Johns Hopkins University","has_results":true},{"nct_id":"NCT06033807","title":"Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients","phase":"","overall_status":"RECRUITING","enrollment_count":31440,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT06593080","title":"The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":30240,"lead_sponsor_name":"Chishala Chabala","has_results":false},{"nct_id":"NCT04923958","title":"Rapid Research in Diagnostics Development for TB Network","phase":"NA","overall_status":"RECRUITING","enrollment_count":26436,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06401434","title":"Evaluation of CAD-based Triage for CXR Interpretation During TB Screening","phase":"NA","overall_status":"COMPLETED","enrollment_count":23835,"lead_sponsor_name":"Freundeskreis Für Internationale Tuberkulosehilfe e.V","has_results":false},{"nct_id":"NCT06963606","title":"Effectiveness of Computer-Aided Detection Chest X-Ray Screening for Improving Tuberculosis Diagnostic Yield in Chinese Primary Health Care Settings: Study Protocol for a Prospective Cluster Randomized Controlled Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":22000,"lead_sponsor_name":"Xuelin Yang","has_results":false},{"nct_id":"NCT05526885","title":"Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa","phase":"NA","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"Klaus Reither","has_results":false},{"nct_id":"NCT06314386","title":"Systems Analysis and Improvement Approach to Prevent TB","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":19560,"lead_sponsor_name":"Boston College","has_results":false},{"nct_id":"NCT02538952","title":"Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":18696,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT03497195","title":"Achieving Tuberculosis (TB) Control In Zambia","phase":"NA","overall_status":"COMPLETED","enrollment_count":18194,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT04119375","title":"Behavior Change and Digital Health Interventions for Improved TB Treatment Outcomes","phase":"NA","overall_status":"COMPLETED","enrollment_count":16146,"lead_sponsor_name":"Massachusetts Institute of Technology","has_results":false},{"nct_id":"NCT05845112","title":"Start Taking Action For TB Diagnosis","phase":"","overall_status":"COMPLETED","enrollment_count":14747,"lead_sponsor_name":"Liverpool School of Tropical Medicine","has_results":false},{"nct_id":"NCT06764576","title":"Patients With Tuberculosis, Mycobacteriosis or Latent Tuberculosis","phase":"","overall_status":"RECRUITING","enrollment_count":13000,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03044158","title":"GeneXpert Performance Evaluation for Linkage to Tuberculosis Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":10644,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT04520113","title":"Kharituwe TB Contact Tracing Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":10579,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":true},{"nct_id":"NCT05640648","title":"Human-centered Design and Communities of Practice to Improve Home-based Tuberculosis Contact Investigation in Uganda","phase":"NA","overall_status":"COMPLETED","enrollment_count":10477,"lead_sponsor_name":"Yale University","has_results":true},{"nct_id":"NCT04677842","title":"European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"PENTA Foundation","has_results":false},{"nct_id":"NCT05581212","title":"TB Case-Finding, Treatment and Prevention Intervention in Thailand","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut de Recherche pour le Developpement","has_results":false},{"nct_id":"NCT06528418","title":"Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"ChromX Health","has_results":false},{"nct_id":"NCT06338215","title":"Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality","phase":"NA","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT04752592","title":"Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB","phase":"NA","overall_status":"COMPLETED","enrollment_count":9097,"lead_sponsor_name":"Norwegian Institute of Public Health","has_results":false},{"nct_id":"NCT02654613","title":"Scaling up TB and HIV Treatment Integration","phase":"NA","overall_status":"COMPLETED","enrollment_count":8000,"lead_sponsor_name":"Centre for the AIDS Programme of Research in South Africa","has_results":false},{"nct_id":"NCT07248423","title":"Start Taking Action for Tuberculosis in Kids","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":7920,"lead_sponsor_name":"Liverpool School of Tropical Medicine","has_results":false},{"nct_id":"NCT05746611","title":"Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":7500,"lead_sponsor_name":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","has_results":false},{"nct_id":"NCT05190146","title":"Epidemiologic Study to Assess the IGRA Positivity in Populations With a High TB Burden","phase":"","overall_status":"COMPLETED","enrollment_count":7203,"lead_sponsor_name":"Gates Medical Research Institute","has_results":false},{"nct_id":"NCT04351685","title":"Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":6940,"lead_sponsor_name":"Serum Institute of India Pvt. Ltd.","has_results":false},{"nct_id":"NCT04433195","title":"Xpert MTB/RIF Test in the Diagnosis of Pulmonary Tuberculosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":6900,"lead_sponsor_name":"Taipei Medical University WanFang Hospital","has_results":false},{"nct_id":"NCT05680415","title":"Clinical Trial of Mica","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6800,"lead_sponsor_name":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","has_results":false},{"nct_id":"NCT06984887","title":"Evaluation of New TB Diagnostic Tests (NATs) in Pakistan","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":6100,"lead_sponsor_name":"Mercy Corps Pakistan","has_results":false},{"nct_id":"NCT03568383","title":"Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5832,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06585683","title":"Post-Trial Tuberculosis Case Finding: A Substudy of CoVPN 3008","phase":"","overall_status":"COMPLETED","enrollment_count":5694,"lead_sponsor_name":"COVID-19 Prevention Network","has_results":false},{"nct_id":"NCT06272812","title":"A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":5500,"lead_sponsor_name":"International AIDS Vaccine Initiative","has_results":false},{"nct_id":"NCT03870061","title":"Evaluation of an Infant Immunization Encouragement Program in Nigeria","phase":"NA","overall_status":"COMPLETED","enrollment_count":5187,"lead_sponsor_name":"GiveWell","has_results":false},{"nct_id":"NCT05280886","title":"Multi-site Cohort Study for the Development of Personalized Pharmacotherapy in Patients With Tuberculosis (TB)","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Inje University","has_results":false},{"nct_id":"NCT02808507","title":"Comparative Effectiveness/Implementation of TB Case Finding in Rural South Africa","phase":"NA","overall_status":"COMPLETED","enrollment_count":4852,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":true},{"nct_id":"NCT07520448","title":"Prevention and Mass Screening of TB in Prisons in Paraguay","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":4500,"lead_sponsor_name":"Universidad Nacional de Caaguazu","has_results":false},{"nct_id":"NCT01547884","title":"Effect of Filarial Infection on Immune Responses in Latent Tuberculosis","phase":"","overall_status":"COMPLETED","enrollment_count":4268,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03739736","title":"TB Reduction Through ART and TB Screening Project","phase":"","overall_status":"UNKNOWN","enrollment_count":4200,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT03074799","title":"Nurse-Led, Symptom-Based Screening of Household Child Contacts of Tuberculosis Index Cases","phase":"NA","overall_status":"COMPLETED","enrollment_count":4054,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04568954","title":"TB-CAPT CORE Truenat Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":3987,"lead_sponsor_name":"Foundation for Innovative New Diagnostics, Switzerland","has_results":false},{"nct_id":"NCT01755598","title":"Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3575,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06022146","title":"TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3520,"lead_sponsor_name":"Huashan Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}